| 19th Jul 2024 10:36 am |
RNS |
Blenrep EMA Filing Acceptance |
| 18th Jul 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 16th Jul 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 15th Jul 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 12th Jul 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 3rd Jul 2024 7:00 am |
RNS |
GSK and CureVac collaboration restructured |
| 1st Jul 2024 3:00 pm |
RNS |
Total Voting Rights |
| 28th Jun 2024 5:37 pm |
RNS |
Statement: Zantac (ranitidine) litigation |
| 24th Jun 2024 7:05 am |
RNS |
Omjjara approved in Japan for myelofibrosis |
| 24th Jun 2024 7:00 am |
RNS |
EMA validates Jemperli marketing authorisation |
| 21st Jun 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 12th Jun 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 11th Jun 2024 7:00 am |
RNS |
Statement: Zantac (ranitidine) litigation |
| 10th Jun 2024 6:27 pm |
RNS |
Statement: Zantac (ranitidine) litigation |
| 10th Jun 2024 7:00 am |
RNS |
FDA approves Arexvy for adults 50-59 at risk |
| 3rd Jun 2024 3:00 pm |
RNS |
Total Voting Rights |
| 3rd Jun 2024 1:03 pm |
RNS |
Unprecedented results in Jemperli trial continue |
| 3rd Jun 2024 7:05 am |
RNS |
ASCO positive Blenrep DREAMM-8 trial results |
| 3rd Jun 2024 7:00 am |
RNS |
Statement: Zantac (ranitidine) litigation |
| 24th May 2024 7:00 am |
RNS |
Statement: Zantac (ranitidine) litigation |
| 21st May 2024 7:00 am |
RNS |
Positive phase III asthma results for depemokimab |
| 20th May 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 17th May 2024 7:00 am |
RNS |
GSK completes sale of shares in Haleon plc |
| 16th May 2024 4:42 pm |
RNS |
GSK announces intention to sell shares in Haleon |
| 14th May 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 13th May 2024 3:00 pm |
RNS |
Block listing Interim Review |
| 8th May 2024 6:21 pm |
RNS |
Result of AGM |
| 8th May 2024 4:57 pm |
RNS |
Board Committee Change |
| 3rd May 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 1st May 2024 3:00 pm |
RNS |
Total Voting Rights |
| 1st May 2024 7:00 am |
RNS |
1st Quarter Results |
| 24th Apr 2024 7:00 am |
RNS |
US FDA accepts new indication filing for Jemperli |
| 19th Apr 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 17th Apr 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 17th Apr 2024 7:05 am |
RNS |
GSK announces additional EAGLE-1 results |
| 17th Apr 2024 7:00 am |
RNS |
Results from long-term data relating to Shingrix |
| 16th Apr 2024 2:11 pm |
RNS |
Amendment - Director/PDMR Shareholding |
| 16th Apr 2024 7:00 am |
RNS |
FDA accepts GSK meningitis vaccine candidate file |
| 15th Apr 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 4th Apr 2024 12:05 pm |
RNS |
Replacement - Total Voting Rights |
